Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States

Aims: Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia associated with increased thromboembolism risk and early mortality. Healthcare resource utilization (HRU) in CAD has not been reported. We aimed to compare HRU of patients with CAD with a matched non-CAD cohort in t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medical economics 2020-08, Vol.23 (8), p.902-907
Hauptverfasser: Su, Jun, Bylsma, Lauren C., Jiang, Xiaohui, Morales Arias, Jaime, Jain, Nisha, Nordyke, Robert J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 907
container_issue 8
container_start_page 902
container_title Journal of medical economics
container_volume 23
creator Su, Jun
Bylsma, Lauren C.
Jiang, Xiaohui
Morales Arias, Jaime
Jain, Nisha
Nordyke, Robert J.
description Aims: Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia associated with increased thromboembolism risk and early mortality. Healthcare resource utilization (HRU) in CAD has not been reported. We aimed to compare HRU of patients with CAD with a matched non-CAD cohort in the United States. Materials and methods: Patients with CAD were identified from 2006 to 2016 in the Optum-Humedica database using CAD terms in clinical notes and hematologist review. Patients were required to have Integrated Delivery Network records and ≥6 months' follow-up before and after the first CAD mention date (index date). Patients with CAD were matched to a non-CAD cohort based on demographics. Multivariate analyses assessed inpatient hospitalizations, outpatient visits, emergency room visits, and transfusion use between cohorts 6 months before and 12 months after the index date. Results: Of 814 patients with CAD, 410 met inclusion criteria and were matched to 3,390 patients without CAD. Mean age of patients with CAD was 68.0 years; approximately 62% were female. In the 12 months after the index date, mean inpatient hospitalizations (0.83 vs. 0.25), outpatient visits (17.26 vs. 6.77), emergency room visits (0.55 vs. 0.32), and transfusion days (1.05 vs. 0.05) were higher for patients with CAD than the matched non-CAD cohort (all p 
doi_str_mv 10.1080/13696998.2020.1764006
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_32362156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2398154929</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-d4824ff7827228c0d76c3c5763795b00f0014dacd303142176090000d6f2fe603</originalsourceid><addsrcrecordid>eNp9kE9rHCEYh6WkNCHNR2jxmMuk_plxxltKSLqFQA5toDcx-rprcHSrDmH76euymxzzXnyR5-cPH4S-UHJFyUS-US6kkHK6YoS1q1H0hIgP6IzKnnYTH_-ctL0x3R46RRelPJM2nFMy0k_olDMuGB3EGVpWoEPdGJ0BZyhpyQbwUn3w_3T1KWI9p7jGJs0zZON1CDvsY1kyWLxtBMRa8Iuvm4YEi_V6HVo6-oitL6ALNBrXDeDH6GvL_Kq6QvmMPjodClwcz3P0eHf7-2bV3T_8-Hnz_b4zPeW1s_3EeufGiY2MTYbYURhuhlHwUQ5PhDhCaG-1sZxw2rPmgcj9P61wzIEg_BxdHt7d5vR3gVLV7IuBEHSEtBTFuJzo0EsmGzocUJNTKRmc2mY_67xTlKi9dPUqXe2lq6P0lvt6rFieZrBvqVfFDbg-AD66lGf9knKwqupdSNllHY0vir_f8R-A7pGo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2398154929</pqid></control><display><type>article</type><title>Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Su, Jun ; Bylsma, Lauren C. ; Jiang, Xiaohui ; Morales Arias, Jaime ; Jain, Nisha ; Nordyke, Robert J.</creator><creatorcontrib>Su, Jun ; Bylsma, Lauren C. ; Jiang, Xiaohui ; Morales Arias, Jaime ; Jain, Nisha ; Nordyke, Robert J.</creatorcontrib><description>Aims: Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia associated with increased thromboembolism risk and early mortality. Healthcare resource utilization (HRU) in CAD has not been reported. We aimed to compare HRU of patients with CAD with a matched non-CAD cohort in the United States. Materials and methods: Patients with CAD were identified from 2006 to 2016 in the Optum-Humedica database using CAD terms in clinical notes and hematologist review. Patients were required to have Integrated Delivery Network records and ≥6 months' follow-up before and after the first CAD mention date (index date). Patients with CAD were matched to a non-CAD cohort based on demographics. Multivariate analyses assessed inpatient hospitalizations, outpatient visits, emergency room visits, and transfusion use between cohorts 6 months before and 12 months after the index date. Results: Of 814 patients with CAD, 410 met inclusion criteria and were matched to 3,390 patients without CAD. Mean age of patients with CAD was 68.0 years; approximately 62% were female. In the 12 months after the index date, mean inpatient hospitalizations (0.83 vs. 0.25), outpatient visits (17.26 vs. 6.77), emergency room visits (0.55 vs. 0.32), and transfusion days (1.05 vs. 0.05) were higher for patients with CAD than the matched non-CAD cohort (all p &lt; .0001). Similarly, in the 6 months before the index date, patients with CAD had higher HRU than matched patients without CAD for all measures evaluated. Limitations: Results of this study are based on patient information from the Optum-Humedica database, which is limited to commercially insured patients and may not represent the overall CAD population. Conclusions: CAD places a substantial burden on patients and healthcare systems. In addition, the high HRU for patients with CAD observed in the 6 months before diagnosis indicates that disease awareness and better diagnostic practices may be needed.</description><identifier>ISSN: 1369-6998</identifier><identifier>EISSN: 1941-837X</identifier><identifier>DOI: 10.1080/13696998.2020.1764006</identifier><identifier>PMID: 32362156</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>autoimmune hemolytic anemia ; cold agglutinin disease ; database analysis ; Disease burden ; healthcare resource utilization</subject><ispartof>Journal of medical economics, 2020-08, Vol.23 (8), p.902-907</ispartof><rights>2020 Sanofi. Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-d4824ff7827228c0d76c3c5763795b00f0014dacd303142176090000d6f2fe603</citedby><cites>FETCH-LOGICAL-c413t-d4824ff7827228c0d76c3c5763795b00f0014dacd303142176090000d6f2fe603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32362156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Su, Jun</creatorcontrib><creatorcontrib>Bylsma, Lauren C.</creatorcontrib><creatorcontrib>Jiang, Xiaohui</creatorcontrib><creatorcontrib>Morales Arias, Jaime</creatorcontrib><creatorcontrib>Jain, Nisha</creatorcontrib><creatorcontrib>Nordyke, Robert J.</creatorcontrib><title>Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States</title><title>Journal of medical economics</title><addtitle>J Med Econ</addtitle><description>Aims: Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia associated with increased thromboembolism risk and early mortality. Healthcare resource utilization (HRU) in CAD has not been reported. We aimed to compare HRU of patients with CAD with a matched non-CAD cohort in the United States. Materials and methods: Patients with CAD were identified from 2006 to 2016 in the Optum-Humedica database using CAD terms in clinical notes and hematologist review. Patients were required to have Integrated Delivery Network records and ≥6 months' follow-up before and after the first CAD mention date (index date). Patients with CAD were matched to a non-CAD cohort based on demographics. Multivariate analyses assessed inpatient hospitalizations, outpatient visits, emergency room visits, and transfusion use between cohorts 6 months before and 12 months after the index date. Results: Of 814 patients with CAD, 410 met inclusion criteria and were matched to 3,390 patients without CAD. Mean age of patients with CAD was 68.0 years; approximately 62% were female. In the 12 months after the index date, mean inpatient hospitalizations (0.83 vs. 0.25), outpatient visits (17.26 vs. 6.77), emergency room visits (0.55 vs. 0.32), and transfusion days (1.05 vs. 0.05) were higher for patients with CAD than the matched non-CAD cohort (all p &lt; .0001). Similarly, in the 6 months before the index date, patients with CAD had higher HRU than matched patients without CAD for all measures evaluated. Limitations: Results of this study are based on patient information from the Optum-Humedica database, which is limited to commercially insured patients and may not represent the overall CAD population. Conclusions: CAD places a substantial burden on patients and healthcare systems. In addition, the high HRU for patients with CAD observed in the 6 months before diagnosis indicates that disease awareness and better diagnostic practices may be needed.</description><subject>autoimmune hemolytic anemia</subject><subject>cold agglutinin disease</subject><subject>database analysis</subject><subject>Disease burden</subject><subject>healthcare resource utilization</subject><issn>1369-6998</issn><issn>1941-837X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9kE9rHCEYh6WkNCHNR2jxmMuk_plxxltKSLqFQA5toDcx-rprcHSrDmH76euymxzzXnyR5-cPH4S-UHJFyUS-US6kkHK6YoS1q1H0hIgP6IzKnnYTH_-ctL0x3R46RRelPJM2nFMy0k_olDMuGB3EGVpWoEPdGJ0BZyhpyQbwUn3w_3T1KWI9p7jGJs0zZON1CDvsY1kyWLxtBMRa8Iuvm4YEi_V6HVo6-oitL6ALNBrXDeDH6GvL_Kq6QvmMPjodClwcz3P0eHf7-2bV3T_8-Hnz_b4zPeW1s_3EeufGiY2MTYbYURhuhlHwUQ5PhDhCaG-1sZxw2rPmgcj9P61wzIEg_BxdHt7d5vR3gVLV7IuBEHSEtBTFuJzo0EsmGzocUJNTKRmc2mY_67xTlKi9dPUqXe2lq6P0lvt6rFieZrBvqVfFDbg-AD66lGf9knKwqupdSNllHY0vir_f8R-A7pGo</recordid><startdate>20200802</startdate><enddate>20200802</enddate><creator>Su, Jun</creator><creator>Bylsma, Lauren C.</creator><creator>Jiang, Xiaohui</creator><creator>Morales Arias, Jaime</creator><creator>Jain, Nisha</creator><creator>Nordyke, Robert J.</creator><general>Taylor &amp; Francis</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200802</creationdate><title>Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States</title><author>Su, Jun ; Bylsma, Lauren C. ; Jiang, Xiaohui ; Morales Arias, Jaime ; Jain, Nisha ; Nordyke, Robert J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-d4824ff7827228c0d76c3c5763795b00f0014dacd303142176090000d6f2fe603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>autoimmune hemolytic anemia</topic><topic>cold agglutinin disease</topic><topic>database analysis</topic><topic>Disease burden</topic><topic>healthcare resource utilization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Su, Jun</creatorcontrib><creatorcontrib>Bylsma, Lauren C.</creatorcontrib><creatorcontrib>Jiang, Xiaohui</creatorcontrib><creatorcontrib>Morales Arias, Jaime</creatorcontrib><creatorcontrib>Jain, Nisha</creatorcontrib><creatorcontrib>Nordyke, Robert J.</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Su, Jun</au><au>Bylsma, Lauren C.</au><au>Jiang, Xiaohui</au><au>Morales Arias, Jaime</au><au>Jain, Nisha</au><au>Nordyke, Robert J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States</atitle><jtitle>Journal of medical economics</jtitle><addtitle>J Med Econ</addtitle><date>2020-08-02</date><risdate>2020</risdate><volume>23</volume><issue>8</issue><spage>902</spage><epage>907</epage><pages>902-907</pages><issn>1369-6998</issn><eissn>1941-837X</eissn><abstract>Aims: Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia associated with increased thromboembolism risk and early mortality. Healthcare resource utilization (HRU) in CAD has not been reported. We aimed to compare HRU of patients with CAD with a matched non-CAD cohort in the United States. Materials and methods: Patients with CAD were identified from 2006 to 2016 in the Optum-Humedica database using CAD terms in clinical notes and hematologist review. Patients were required to have Integrated Delivery Network records and ≥6 months' follow-up before and after the first CAD mention date (index date). Patients with CAD were matched to a non-CAD cohort based on demographics. Multivariate analyses assessed inpatient hospitalizations, outpatient visits, emergency room visits, and transfusion use between cohorts 6 months before and 12 months after the index date. Results: Of 814 patients with CAD, 410 met inclusion criteria and were matched to 3,390 patients without CAD. Mean age of patients with CAD was 68.0 years; approximately 62% were female. In the 12 months after the index date, mean inpatient hospitalizations (0.83 vs. 0.25), outpatient visits (17.26 vs. 6.77), emergency room visits (0.55 vs. 0.32), and transfusion days (1.05 vs. 0.05) were higher for patients with CAD than the matched non-CAD cohort (all p &lt; .0001). Similarly, in the 6 months before the index date, patients with CAD had higher HRU than matched patients without CAD for all measures evaluated. Limitations: Results of this study are based on patient information from the Optum-Humedica database, which is limited to commercially insured patients and may not represent the overall CAD population. Conclusions: CAD places a substantial burden on patients and healthcare systems. In addition, the high HRU for patients with CAD observed in the 6 months before diagnosis indicates that disease awareness and better diagnostic practices may be needed.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>32362156</pmid><doi>10.1080/13696998.2020.1764006</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1369-6998
ispartof Journal of medical economics, 2020-08, Vol.23 (8), p.902-907
issn 1369-6998
1941-837X
language eng
recordid cdi_pubmed_primary_32362156
source EZB-FREE-00999 freely available EZB journals
subjects autoimmune hemolytic anemia
cold agglutinin disease
database analysis
Disease burden
healthcare resource utilization
title Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T08%3A59%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Healthcare%20resource%20utilization%20among%20commercially%20insured%20patients%20with%20cold%20agglutinin%20disease%20in%20the%20United%20States&rft.jtitle=Journal%20of%20medical%20economics&rft.au=Su,%20Jun&rft.date=2020-08-02&rft.volume=23&rft.issue=8&rft.spage=902&rft.epage=907&rft.pages=902-907&rft.issn=1369-6998&rft.eissn=1941-837X&rft_id=info:doi/10.1080/13696998.2020.1764006&rft_dat=%3Cproquest_pubme%3E2398154929%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2398154929&rft_id=info:pmid/32362156&rfr_iscdi=true